Physician profile
Mark S Souder
NPI 1245218973
$24,326.18
in general payments reported to CMS, 2019-2025
64 companies · $3,050 in 2025
The $3,050 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,654 · 2020: $2,587 · 2021: $3,368 · 2022: $6,180 · 2023: $2,479 · 2024: $4,007 · 2025: $3,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,462 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $23.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,462.46 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $23.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,845.98 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,113.43 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,603.39 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Supernus Pharmaceuticals, INC. | $1,438.36 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Amgen INC. | $1,205.49 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $1,191.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,042.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $909.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $809.92 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Pfizer INC. | $778.11 | 2019-2024 | |
| Corium, LLC | $711.77 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $580.21 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $580.16 | 2019-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472.09 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $466.29 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Souder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.